Takaisin Tulosta

Insuliininpuutosdiabetes, näytönastekatsausten kirjallisuusviitteet

Lisätietoa aiheesta
Käypä hoito -toimitus
12.11.2025

Kirjallisuusviiteluettelosta löytyy koottuna Käypä hoito -suosituksen Insuliininpuutosdiabetes «Insuliininpuutosdiabetes»1 näytönastekatsauksissa arvioitu kirjallisuus.

Kirjallisuutta

  1. Adolfsson P, Hartvig NV, Kaas A, ym. Increased Time in Range and Fewer Missed Bolus Injections After Introduction of a Smart Connected Insulin Pen. Diabetes Technol Ther 2020;22(10):709-718 «PMID: 32003590»PubMed
  2. AHA, ACC, National Heart, Lung, and Blood Institute, ym. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006;47(10):2130-9 «PMID: 16697342»PubMed
  3. American Diabetes Association Professional Practice Committee. Erratum. 7. Diabetes Technology: Standards of Care in Diabetes-2025. Diabetes Care 2025;48(Suppl. 1):S146-S166. Diabetes Care 2025;48(4):666
  4. Amigó J, Ortiz-Zúñiga Á, de Urbina AMO, ym. Switching from treatment with sensor augmented pump to hybrid closed loop system in type 1 diabetes: Impact on glycemic control and neuropsychological tests in the real world. Diabetes Res Clin Pract 2023;201():110730 «PMID: 37236365»PubMed
  5. Anderson SM, Buckingham BA, Breton MD, ym. Hybrid Closed-Loop Control Is Safe and Effective for People with Type 1 Diabetes Who Are at Moderate to High Risk for Hypoglycemia. Diabetes Technol Ther 2019;21(6):356-363 «PMID: 31095423»PubMed
  6. Azahaf S, Beunen K, Van Wilder N, ym. Cost-effectiveness of advanced hybrid closed loop therapy compared to standard insulin therapy for type 1 diabetes in pregnancy: an economic evaluation of the CRISTAL trial. EClinicalMedicine 2025;81():103106 «PMID: 40034575»PubMed
  7. Barnard KD, Wysocki T, Allen JM, ym. Closing the loop overnight at home setting: psychosocial impact for adolescents with type 1 diabetes and their parents. BMJ Open Diabetes Res Care 2014;2(1):e000025 «PMID: 25452866»PubMed
  8. Battelino T, Conget I, Olsen B, ym. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 2012;55(12):3155-62 «PMID: 22965294»PubMed
  9. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Beck RW, Hirsch IB, ym. The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care 2009;32(8):1378-83 «PMID: 19429875»PubMed
  10. Beck RW, Kanapka LG, Breton MD, ym. A Meta-Analysis of Randomized Trial Outcomes for the t:slim X2 Insulin Pump with Control-IQ Technology in Youth and Adults from Age 2 to 72. Diabetes Technol Ther 2023;25(5):329-342 «PMID: 37067353»PubMed
  11. Beck RW, Riddlesworth T, Ruedy K, ym. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA 2017;317(4):371-378 «PMID: 28118453»PubMed
  12. Beck RW, Russell SJ, Damiano ER, ym. A Multicenter Randomized Trial Evaluating Fast-Acting Insulin Aspart in the Bionic Pancreas in Adults with Type 1 Diabetes. Diabetes Technol Ther 2022;24(10):681-696 «PMID: 36173235»PubMed
  13. Benhamou PY, Adenis A, Lablanche S, ym. First Generation of a Modular Interoperable Closed-Loop System for Automated Insulin Delivery in Patients With Type 1 Diabetes: Lessons From Trials and Real-Life Data. J Diabetes Sci Technol 2023;17(6):1433-1439 «PMID: 37449762»PubMed
  14. Benhamou PY, Adenis A, Lebbad H, ym. One-year real-world performance of the DBLG1 closed-loop system: Data from 3706 adult users with type 1 diabetes in Germany. Diabetes Obes Metab 2023;25(6):1607-1613 «PMID: 36751978»PubMed
  15. Bergenstal RM, Bailey TS, Rodbard D, ym. Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections. Diabetes Care 2017;40(4):554-560 «PMID: 28115474»PubMed
  16. Bergenstal RM, Garg S, Weinzimer SA, ym. Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes. JAMA 2016;316(13):1407-1408 «PMID: 27629148»PubMed
  17. Bergenstal RM, Tamborlane WV, Ahmann A, ym. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010;363(4):311-20 «PMID: 20587585»PubMed
  18. Biester T, Muller I, von dem Berge T, ym. Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study. Diabetes Obes Metab 2021;23(2):599-608 «PMID: 33217117»PubMed
  19. Bionic Pancreas Research Group, Russell SJ, Beck RW, ym. Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. N Engl J Med 2022;387(13):1161-1172 «PMID: 36170500»PubMed
  20. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Bode B, Beck RW, ym. Sustained benefit of continuous glucose monitoring on A1C, glucose profiles, and hypoglycemia in adults with type 1 diabetes. Diabetes Care 2009;32(11):2047-9 «PMID: 19675193»PubMed
  21. Boughton CK, Hovorka R. The role of automated insulin delivery technology in diabetes. Diabetologia 2024;67(10):2034-2044 «PMID: 38740602»PubMed
  22. Brown SA, Kovatchev BP, Raghinaru D, ym. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. N Engl J Med 2019;381(18):1707-1717 «PMID: 31618560»PubMed
  23. Buckingham BA, Christiansen MP, Forlenza GP, ym. Performance of the Omnipod Personalized Model Predictive Control Algorithm with Meal Bolus Challenges in Adults with Type 1 Diabetes. Diabetes Technol Ther 2018;20(9):585-595 «PMID: 30070928»PubMed
  24. Bueno NB, de Melo IS, de Oliveira SL, ym. Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials. Br J Nutr 2013;110(7):1178-87 «PMID: 23651522»PubMed
  25. Calhoun P, Price D, Beck RW. Glycemic Improvement Using Continuous Glucose Monitoring by Baseline Time in Range: Subgroup Analyses from the DIAMOND Type 1 Diabetes Study. Diabetes Technol Ther 2021;23(3):230-233 «PMID: 33006904»PubMed
  26. Cannon CP, Braunwald E, McCabe CH ym. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504
  27. Cannon CP, Steinberg BA, Murphy SA, ym. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006;48(3):438-45 «PMID: 16875966»PubMed
  28. Carlson AL, Sherr JL, Shulman DI, ym. Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes. Diabetes Technol Ther 2022;24(3):178-189 «PMID: 34694909»PubMed
  29. Castellanos LE, Russell SJ, Damiano ER, ym. The Insulin-Only Bionic Pancreas Improves Glycemic Control in Non-Hispanic White and Minority Adults and Children With Type 1 Diabetes. Diabetes Care 2023;46(6):1185-1190 «PMID: 37000680»PubMed
  30. Champakanath A, Akturk HK, Alonso GT, ym. Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study. Diabetes Care 2022;45(3):750-753 «PMID: 35018417»PubMed
  31. Chan K, Hansen K, Muratov S, ym. Smart connected insulin dose monitoring technologies versus standard of care: a Canadian cost-effectiveness analysis. J Comp Eff Res 2024;13(3):e230124 «PMID: 38205726»PubMed
  32. Chico A, Navas de Solís S, Lainez M, ym. Efficacy, Safety, and Satisfaction with the Accu-Chek Insight with Diabeloop Closed-Loop System in Subjects with Type 1 Diabetes: A Multicenter Real-World Study. Diabetes Technol Ther 2023;25(4):242-249 «PMID: 36724301»PubMed
  33. Chien A, Thanasekaran S, Gaetano A, ym. Potential cost savings in the United States from a reduction in sensor-detected severe hypoglycemia among users of the InPen smart insulin pen system. J Manag Care Spec Pharm 2023;29(3):285-292 «PMID: 36692907»PubMed
  34. Clifton PM, Condo D, Keogh JB. Long term weight maintenance after advice to consume low carbohydrate, higher protein diets--a systematic review and meta analysis. Nutr Metab Cardiovasc Dis 2014;24(3):224-35 «PMID: 24472635»PubMed
  35. Considine EG, Sherr JL. Real-World Evidence of Automated Insulin Delivery System Use. Diabetes Technol Ther 2024;26(S3):53-65 «PMID: 38377315»PubMed
  36. Cordero TL, Dai Z, Arrieta A, ym. Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor. Diabetes Technol Ther 2023;25(9):652-658 «PMID: 37252734»PubMed
  37. Correction to Lancet Diabetes Endocrinol 2018; 6: 954-65. Lancet Diabetes Endocrinol 2019;7(3):e3
  38. D'Aiuto F, Gkranias N, Bhowruth D, ym. Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial. Lancet Diabetes Endocrinol 2018;6(12):954-965 «PMID: 30472992»PubMed
  39. Dandona P, Mathieu C, Phillip M, ym. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. Diabetes Care 2018;41(12):2552-2559 «PMID: 30352894»PubMed
  40. Danne TPA, Joubert M, Hartvig NV, ym. Association Between Treatment Adherence and Continuous Glucose Monitoring Outcomes in People With Diabetes Using Smart Insulin Pens in a Real-World Setting. Diabetes Care 2024;47(6):995-1003 «PMID: 38569055»PubMed
  41. Davies MJ, Gross JL, Ono Y, ym. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial. Diabetes Obes Metab 2014;16(10):922-30 «PMID: 24702700»PubMed
  42. de Lemos JA, Blazing MA, Wiviott SD, ym. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292(11):1307-16 «PMID: 15337732»PubMed
  43. Dicembrini I, Cosentino C, Monami M, ym. Effects of real-time continuous glucose monitoring in type 1 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol 2021;58(4):401-410 «PMID: 32789691»PubMed
  44. Dressler A, Reithofer E, Trimmel-Schwahofer P, ym. Type 1 diabetes and epilepsy: efficacy and safety of the ketogenic diet. Epilepsia 2010;51(6):1086-9 «PMID: 20345934»PubMed
  45. Ekhlaspour L, Forlenza GP, Chernavvsky D, ym. Closed loop control in adolescents and children during winter sports: Use of the Tandem Control-IQ AP system. Pediatr Diabetes 2019;20(6):759-768 «PMID: 31099946»PubMed
  46. Ekhlaspour L, Raghinaru D, Forlenza GP, ym. Outcomes in Pump- and CGM-Baseline Use Subgroups in the International Diabetes Closed-Loop Trial. J Diabetes Sci Technol 2023;17(4):935-942 «PMID: 35473359»PubMed
  47. Elliott J, Jacques RM, Kruger J, ym. Substantial reductions in the number of diabetic ketoacidosis and severe hypoglycaemia episodes requiring emergency treatment lead to reduced costs after structured education in adults with Type 1 diabetes. Diabet Med 2014;31(7):847-53 «PMID: 24654672»PubMed
  48. Forlenza GP, Carlson AL, Galindo RJ, ym. Real-World Evidence Supporting Tandem Control-IQ Hybrid Closed-Loop Success in the Medicare and Medicaid Type 1 and Type 2 Diabetes Populations. Diabetes Technol Ther 2022;24(11):814-823 «PMID: 35763323»PubMed
  49. Forlenza GP, DeSalvo DJ, Aleppo G, ym. Real-World Evidence of Omnipod(®) 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes. Diabetes Technol Ther 2024;26(8):514-525 «PMID: 38375861»PubMed
  50. Forlenza GP, Ekhlaspour L, Breton M, ym. Successful At-Home Use of the Tandem Control-IQ Artificial Pancreas System in Young Children During a Randomized Controlled Trial. Diabetes Technol Ther 2019;21(4):159-169 «PMID: 30888835»PubMed
  51. Forlenza GP, Pinhas-Hamiel O, Liljenquist DR, ym. Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes. Diabetes Technol Ther 2019;21(1):11-19 «PMID: 30585770»PubMed
  52. Garber AJ, King AB, Del Prato S, ym. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012;379(9825):1498-507 «PMID: 22521072»PubMed
  53. Garcia-Tirado J, Farhy L, Nass R, ym. Automated Insulin Delivery with SGLT2i Combination Therapy in Type 1 Diabetes. Diabetes Technol Ther 2022;24(7):461-470 «PMID: 35255229»PubMed
  54. Gardner D, Lakkad M, Qiu Z, ym. The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System Compared to Standard Management of Type 1 Diabetes in a Singapore Setting. Diabetes Technol Ther 2024;26(5):324-334 «PMID: 38215206»PubMed
  55. Garg SK, Kaur G, Haider Z, ym. Efficacy of Semaglutide in Overweight and Obese Patients with Type 1 Diabetes. Diabetes Technol Ther 2024;26(3):184-189 «PMID: 38444317»PubMed
  56. Garg SK, Weinzimer SA, Tamborlane WV, ym. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes. Diabetes Technol Ther 2017;19(3):155-163 «PMID: 28134564»PubMed
  57. Grassi B, Gómez AM, Calliari LE, ym. Real-world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniMed automated insulin delivery system. Diabetes Obes Metab 2023;25(6):1688-1697 «PMID: 36789699»PubMed
  58. Haidar A, Lovblom LE, Cardinez N, ym. Empagliflozin add-on therapy to closed-loop insulin delivery in type 1 diabetes: a 2 × 2 factorial randomized crossover trial. Nat Med 2022;28(6):1269-1276 «PMID: 35551290»PubMed
  59. Hampp C, Swain RS, Horgan C, ym. Erratum. Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis. Diabetes Care 2020;43:90-97. Diabetes Care 2020;43(9):2324 «PMID: 32647048»PubMed
  60. Heller S, Buse J, Fisher M, ym. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012;379(9825):1489-97 «PMID: 22521071»PubMed
  61. Hellman J, Hartvig NV, Kaas A, ym. Associations of bolus insulin injection frequency and smart pen engagement with glycaemic control in people living with type 1 diabetes. Diabetes Obes Metab 2024;26(1):301-310 «PMID: 37926903»PubMed
  62. Henry RR, Thakkar P, Tong C, ym. Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes. Diabetes Care 2015;38(12):2258-65 «PMID: 26486192»PubMed
  63. Home PD, Bergenstal RM, Bolli GB, ym. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). Diabetes Care 2015;38(12):2217-25 «PMID: 26084341»PubMed
  64. Hopkins D, Lawrence I, Mansell P, ym. Improved biomedical and psychological outcomes 1 year after structured education in flexible insulin therapy for people with type 1 diabetes: the U.K. DAFNE experience. Diabetes Care 2012;35(8):1638-42 «PMID: 22619082»PubMed
  65. Isitt JJ, Roze S. Long-term cost-effectiveness of Dexcom G6 real-time continuous glucose monitoring system in people with type 1 diabetes in Australia: Response to letter from Hellmund, Richard and Welsh, Zoe. Diabet Med 2023;40(2):e14989 «PMID: 36271634»PubMed
  66. Jiao Y, Lin R, Hua X, ym. A systematic review: Cost-effectiveness of continuous glucose monitoring compared to self-monitoring of blood glucose in type 1 diabetes. Endocrinol Diabetes Metab 2022;5(6):e369 «PMID: 36112608»PubMed
  67. Johnston BC, Kanters S, Bandayrel K, ym. Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. JAMA 2014;312(9):923-33 «PMID: 25182101»PubMed
  68. Karageorgiou V, Papaioannou TG, Bellos I, ym. Effectiveness of artificial pancreas in the non-adult population: A systematic review and network meta-analysis. Metabolism 2019;90():20-30 «PMID: 30321535»PubMed
  69. Kaur H, Schneider N, Pyle L, ym. Efficacy of Hybrid Closed-Loop System in Adults with Type 1 Diabetes and Gastroparesis. Diabetes Technol Ther 2019;21(12):736-739 «PMID: 31347928»PubMed
  70. Keskinen P, Korhonen S, Kupila A, ym. First-phase insulin response in young healthy children at genetic and immunological risk for Type I diabetes. Diabetologia 2002;45(12):1639-48 «PMID: 12488953»PubMed
  71. Kommareddi M, Wherry K. Cost-effectiveness of the MiniMed 780G system for type 1 diabetes. Am J Manag Care 2025;31(4):e79-e86 «PMID: 40227447»PubMed
  72. Kovatchev B, Anderson SM, Raghinaru D, ym. Randomized Controlled Trial of Mobile Closed-Loop Control. Diabetes Care 2020;43(3):607-615 «PMID: 31937608»PubMed
  73. Krebs JD, Parry Strong A, Cresswell P, ym. A randomised trial of the feasibility of a low carbohydrate diet vs standard carbohydrate counting in adults with type 1 diabetes taking body weight into account. Asia Pac J Clin Nutr 2016;25(1):78-84 «PMID: 26965765»PubMed
  74. Kruger D, Kass A, Lonier J, ym. A Multicenter Randomized Trial Evaluating the Insulin-Only Configuration of the Bionic Pancreas in Adults with Type 1 Diabetes. Diabetes Technol Ther 2022;24(10):697-711 «PMID: 36173236»PubMed
  75. Kudva YC, Henderson RJ, Kanapka LG, ym. Automated Insulin Delivery in Elderly with Type 1 Diabetes: A Prespecified Analysis of the Extension Phase. Diabetes Technol Ther 2025;27(7):572-575 «PMID: 40067490»PubMed
  76. LaGasse JM, Brantley MS, Leech NJ, ym. Successful prospective prediction of type 1 diabetes in schoolchildren through multiple defined autoantibodies: an 8-year follow-up of the Washington State Diabetes Prediction Study. Diabetes Care 2002;25(3):505-11 «PMID: 11874938»PubMed
  77. Lal RA, Basina M, Maahs DM, ym. One Year Clinical Experience of the First Commercial Hybrid Closed-Loop System. Diabetes Care 2019;42(12):2190-2196 «PMID: 31548247»PubMed
  78. LaRosa JC, Grundy SM, Waters DD, ym. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352(14):1425-35 «PMID: 15755765»PubMed
  79. Lind M, Ólafsdóttir AF, Hirsch IB, ym. Sustained Intensive Treatment and Long-term Effects on HbA(1c) Reduction (SILVER Study) by CGM in People With Type 1 Diabetes Treated With MDI. Diabetes Care 2021;44(1):141-149 «PMID: 33199470»PubMed
  80. Lind M, Polonsky W, Hirsch IB, ym. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial. JAMA 2017;317(4):379-387 «PMID: 28118454»PubMed
  81. Lynch J, Kanapka LG, Russell SJ, ym. The Insulin-Only Bionic Pancreas Pivotal Trial Extension Study: A Multi-Center Single-Arm Evaluation of the Insulin-Only Configuration of the Bionic Pancreas in Adults and Youth with Type 1 Diabetes. Diabetes Technol Ther 2022;24(10):726-736 «PMID: 36173238»PubMed
  82. MacLeod J, Im GH, Smith M, ym. Shining the Spotlight on Multiple Daily Insulin Therapy: Real-World Evidence of the InPen Smart Insulin Pen. Diabetes Technol Ther 2024;26(1):33-39 «PMID: 37855818»PubMed
  83. Mansoor N, Vinknes KJ, Veierød MB, ym. Effects of low-carbohydrate diets v. low-fat diets on body weight and cardiovascular risk factors: a meta-analysis of randomised controlled trials. Br J Nutr 2016;115(3):466-79 «PMID: 26768850»PubMed
  84. Marjamäki L, Niinistö S, Kenward MG, ym. Maternal intake of vitamin D during pregnancy and risk of advanced beta cell autoimmunity and type 1 diabetes in offspring. Diabetologia 2010;53(8):1599-607 «PMID: 20369220»PubMed
  85. Maruyama T, Shimada A, Kanatsuka A, ym. Multicenter prevention trial of slowly progressive type 1 diabetes with small dose of insulin (the Tokyo study): preliminary report. Ann N Y Acad Sci 2003;1005():362-9 «PMID: 14679093»PubMed
  86. Mathieu C, Ahmed W, Gillard P, ym. The Health Economics of Automated Insulin Delivery Systems and the Potential Use of Time in Range in Diabetes Modeling: A Narrative Review. Diabetes Technol Ther 2024;26(S3):66-75 «PMID: 38377319»PubMed
  87. Mathieu C, Dandona P, Gillard P, ym. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. Diabetes Care 2018;41(9):1938-1946 «PMID: 30026335»PubMed
  88. Matsuhisa M, Koyama M, Cheng X, ym. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1). Diabetes Obes Metab 2016;18(4):375-83 «PMID: 26662964»PubMed
  89. McVean J, Forlenza GP, Beck RW, ym. Effect of Tight Glycemic Control on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial. JAMA 2023;329(12):980-989 «PMID: 36826834»PubMed
  90. Messer LH, Buckingham BA, Cogen F, ym. Positive Impact of the Bionic Pancreas on Diabetes Control in Youth 6-17 Years Old with Type 1 Diabetes: A Multicenter Randomized Trial. Diabetes Technol Ther 2022;24(10):712-725 «PMID: 36173237»PubMed
  91. Miller KM, Bauza C, Kanapka LG, ym. Continuous Glucose Monitoring Provides Durable Glycemic Benefit in Adolescents and Young Adults with Type 1 Diabetes: 12-Month Follow-Up Results. Pediatr Diabetes 2023;2023():6718115 «PMID: 40303270»PubMed
  92. Mrena S, Virtanen SM, Laippala P, ym. Models for predicting type 1 diabetes in siblings of affected children. Diabetes Care 2006;29(3):662-7 «PMID: 16505523»PubMed
  93. Mulinacci G, Alonso GT, Snell-Bergeon JK, ym. Glycemic Outcomes with Early Initiation of Continuous Glucose Monitoring System in Recently Diagnosed Patients with Type 1 Diabetes. Diabetes Technol Ther 2019;21(1):6-10 «PMID: 30575413»PubMed
  94. Mustonen J, Rautiainen P, Lamidi ML, ym. Long-Term Health Economic Evaluation of Intermittently Scanned Glucose Monitoring Compared with Self-Monitoring Blood Glucose in a Real-World Setting in Finnish Adult Individuals with Type 1 Diabetes. Diabetes Technol Ther 2024;26(12):918-924 «PMID: 38842899»PubMed
  95. Naude CE, Schoonees A, Senekal M, ym. Low carbohydrate versus isoenergetic balanced diets for reducing weight and cardiovascular risk: a systematic review and meta-analysis. PLoS One 2014;9(7):e100652 «PMID: 25007189»PubMed
  96. Nielsen JV, Jönsson E, Ivarsson A. A low carbohydrate diet in type 1 diabetes: clinical experience--a brief report. Ups J Med Sci 2005;110(3):267-73 «PMID: 16454166»PubMed
  97. Niskanen LK, Tuomi T, Karjalainen J, ym. GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis. Diabetes Care 1995;18(12):1557-65 «PMID: 8722051»PubMed
  98. O'Connell MA, Donath S, O'Neal DN, ym. Glycaemic impact of patient-led use of sensor-guided pump therapy in type 1 diabetes: a randomised controlled trial. Diabetologia 2009;52(7):1250-7 «PMID: 19396424»PubMed
  99. O'Keefe JH Jr, Cordain L, Harris WH, ym. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 2004;43(11):2142-6 «PMID: 15172426»PubMed
  100. Ólafsdóttir AF, Bolinder J, Heise T, ym. The majority of people with type 1 diabetes and multiple daily insulin injections benefit from using continuous glucose monitoring: An analysis based on the GOLD randomized trial (GOLD-5). Diabetes Obes Metab 2021;23(2):619-630 «PMID: 33200487»PubMed
  101. Oliver N, Gimenez M, Calhoun P, ym. Continuous Glucose Monitoring in People With Type 1 Diabetes on Multiple-Dose Injection Therapy: The Relationship Between Glycemic Control and Hypoglycemia. Diabetes Care 2020;43(1):53-58 «PMID: 31530662»PubMed
  102. Palomäki A, Kovanen PT. LDL-kolesterolin luonnonmukainen pitoisuus on saavutettavissa turvallisesti. Duodecim 2006;122(14):1747-56 «PMID: 17091709»PubMed
  103. Park J, Ntelis S, Yunasan E, ym. Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis. J Clin Endocrinol Metab 2023;109(1):279-292 «PMID: 37561012»PubMed
  104. Pasqua MR, Jafar A, Kobayati A, ym. Low-Dose Empagliflozin as Adjunct to Hybrid Closed-Loop Insulin Therapy in Adults With Suboptimally Controlled Type 1 Diabetes: A Randomized Crossover Controlled Trial. Diabetes Care 2023;46(1):165-172 «PMID: 36331522»PubMed
  105. Pedersen TR, Faergeman O, Kastelein JJ, ym. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294(19):2437-45 «PMID: 16287954»PubMed
  106. Phillip M, Mathieu C, Lind M, ym. Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies. Diabetes Obes Metab 2021;23(2):549-560 «PMID: 33145944»PubMed
  107. Pratley RE, Kanapka LG, Rickels MR, ym. Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes: A Randomized Clinical Trial. JAMA 2020;323(23):2397-2406 «PMID: 32543682»PubMed
  108. Ranjan A, Schmidt S, Damm-Frydenberg C, ym. Low-Carbohydrate Diet Impairs the Effect of Glucagon in the Treatment of Insulin-Induced Mild Hypoglycemia: A Randomized Crossover Study. Diabetes Care 2017;40(1):132-135 «PMID: 27797928»PubMed
  109. Rankin D, Barnard K, Elliott J, ym. Type 1 diabetes patients' experiences of, and need for, social support after attending a structured education programme: a qualitative longitudinal investigation. J Clin Nurs 2014;23(19-20):2919-27 «PMID: 24443789»PubMed
  110. Renard E, Tubiana-Rufi N, Bonnemaison-Gilbert E, ym. Closed-loop driven by control-to-range algorithm outperforms threshold-low-glucose-suspend insulin delivery on glucose control albeit not on nocturnal hypoglycaemia in prepubertal patients with type 1 diabetes in a supervised hotel setting. Diabetes Obes Metab 2019;21(1):183-187 «PMID: 30047223»PubMed
  111. REPOSE Study Group. Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE). BMJ 2017;356():j1285 «PMID: 28360027»PubMed
  112. Riddle MC, Bolli GB, Ziemen M, ym. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care 2014;37(10):2755-62 «PMID: 25078900»PubMed
  113. Rodbard HW, Peters AL, Slee A, ym. The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes. Diabetes Care 2017;40(2):171-180 «PMID: 27899497»PubMed
  114. Rosenstock J, Marquard J, Laffel LM, ym. Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. Diabetes Care 2018;41(12):2560-2569 «PMID: 30287422»PubMed
  115. Schmidt S, Nørgaard K. Sensor-augmented pump therapy at 36 months. Diabetes Technol Ther 2012;14(12):1174-7 «PMID: 23016516»PubMed
  116. Seyed Ahmadi S, Westman K, Pivodic A, ym. The Association Between HbA(1c) and Time in Hypoglycemia During CGM and Self-Monitoring of Blood Glucose in People With Type 1 Diabetes and Multiple Daily Insulin Injections: A Randomized Clinical Trial (GOLD-4). Diabetes Care 2020;43(9):2017-2024 «PMID: 32641374»PubMed
  117. Sherr JL, Buckingham BA, Forlenza GP, ym. Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions. Diabetes Technol Ther 2020;22(3):174-184 «PMID: 31596130»PubMed
  118. Sherr JL, Cengiz E, Palerm CC, ym. Reduced hypoglycemia and increased time in target using closed-loop insulin delivery during nights with or without antecedent afternoon exercise in type 1 diabetes. Diabetes Care 2013;36(10):2909-14 «PMID: 23757427»PubMed
  119. Simpson TC, Clarkson JE, Worthington HV, ym. Treatment of periodontitis for glycaemic control in people with diabetes mellitus. Cochrane Database Syst Rev 2022;4(4):CD004714 «PMID: 35420698»PubMed
  120. Šoupal J, Parkin CG. Response to Comment on Šoupal et al. Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-up From the COMISAIR Study. Diabetes Care 2020;43:37-43. Diabetes Care 2020;43(4):e54-e55 «PMID: 32198289»PubMed
  121. Stahl-Pehe A, Shokri-Mashhadi N, Wirth M, ym. Efficacy of automated insulin delivery systems in people with type 1 diabetes: a systematic review and network meta-analysis of outpatient randomised controlled trials. EClinicalMedicine 2025;82():103190 «PMID: 40270713»PubMed
  122. Stamati A, Christoforidis A. Automated insulin delivery in pregnant women with type 1 diabetes mellitus: a systematic review and meta-analysis. Acta Diabetol 2025;62(4):441-452 «PMID: 39792171»PubMed
  123. Tauschmann M, Thabit H, Bally L, ym. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet 2018;392(10155):1321-1329 «PMID: 30292578»PubMed
  124. Teixeira T, Godoi A, Romeiro P, Novaes JVLC, de Freitas Faria FM, Pereira S et al (2024) Efficacy of automated insulin delivery in pregnant women with type 1 diabetes: a meta-analysis and trial sequential analysis of randomized controlled trials. Acta Diabetol 61(7):831–840
  125. Teo E, Hassan N, Tam W, ym. Effectiveness of continuous glucose monitoring in maintaining glycaemic control among people with type 1 diabetes mellitus: a systematic review of randomised controlled trials and meta-analysis. Diabetologia 2022;65(4):604-619 «PMID: 35141761»PubMed
  126. Teoh IH, Prabhu J, Mubita W, ym. Real-Time Continuous Glucose Monitoring Benefits Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes Irrespective of Insulin Delivery Modality: Subanalysis of the MILLENNIAL Study. J Diabetes Sci Technol 2022;16(1):252-253 «PMID: 34632831»PubMed
  127. Thomas D, Elliott EJ. Low glycaemic index, or low glycaemic load, diets for diabetes mellitus. Cochrane Database Syst Rev 2009;2009(1):CD006296 «PMID: 19160276»PubMed
  128. Tillman JB, Beck RW, Polonsky WH, ym. Observed Glycemic and Psychosocial Benefits in the Prospective Bigfoot Unity Real World Study: A 6-Month Analysis. J Clin Endocrinol Metab 2025;110(8):2134-2146 «PMID: 39546625»PubMed
  129. Tobias DK, Chen M, Manson JE, ym. Effect of low-fat diet interventions versus other diet interventions on long-term weight change in adults: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2015;3(12):968-79 «PMID: 26527511»PubMed
  130. Troncone A, Bonfanti R, Iafusco D, ym. Evaluating the Experience of Children With Type 1 Diabetes and Their Parents Taking Part in an Artificial Pancreas Clinical Trial Over Multiple Days in a Diabetes Camp Setting. Diabetes Care 2016;39(12):2158-2164 «PMID: 27852685»PubMed
  131. Tumminia A, Crimi S, Sciacca L, ym. Efficacy of real-time continuous glucose monitoring on glycaemic control and glucose variability in type 1 diabetic patients treated with either insulin pumps or multiple insulin injection therapy: a randomized controlled crossover trial. Diabetes Metab Res Rev 2015;31(1):61-8 «PMID: 24816997»PubMed
  132. Turner R, Stratton I, Horton V, ym. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997;350(9087):1288-93 «PMID: 9357409»PubMed
  133. Vallivaara HL, Leppänen HA, Mustonen J, ym. Long-term health economic evaluation of automated insulin delivery system compared with continuous subcutaneous insulin infusion pumps and CGM in a real-world setting in Finnish paediatric and adult individuals with type 1 diabetes. Diabetes Obes Metab 2025;27(9):4793-4801 «PMID: 40574544»PubMed
  134. Wadwa RP, Reed ZW, Buckingham BA, ym. Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes. N Engl J Med 2023;388(11):991-1001 «PMID: 36920756»PubMed
  135. Wan W, Skandari MR, Minc A, ym. Cost-effectiveness of Initiating an Insulin Pump in T1D Adults Using Continuous Glucose Monitoring Compared with Multiple Daily Insulin Injections: The DIAMOND Randomized Trial. Med Decis Making 2018;38(8):942-953 «PMID: 30403576»PubMed
  136. Weissberg-Benchell J, Hessler D, Polonsky WH, ym. Psychosocial Impact of the Bionic Pancreas During Summer Camp. J Diabetes Sci Technol 2016;10(4):840-4 «PMID: 26993252»PubMed
  137. Weissberg-Benchell J, Vesco AT, Shapiro J, ym. Psychosocial Impact of the Insulin-Only iLet Bionic Pancreas for Adults, Youth, and Caregivers of Youth with Type 1 Diabetes. Diabetes Technol Ther 2023;25(10):705-717 «PMID: 37523175»PubMed
  138. Wheeler ML, Dunbar SA, Jaacks LM, ym. Macronutrients, food groups, and eating patterns in the management of diabetes: a systematic review of the literature, 2010. Diabetes Care 2012;35(2):434-45 «PMID: 22275443»PubMed
  139. William J, McCluskey J, Gleeson N. RT-CGM in conjunction with CSII vs MDI in optimizing glycaemic control in T1DM: Systemic review and meta-analysis. Endocrinol Diabetes Metab 2022;5(2):e00324 «PMID: 35118826»PubMed
  140. Wiviott SD, Cannon CP, Morrow DA, ym. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005;46(8):1411-6 «PMID: 16226163»PubMed
  141. Yang Q, Hao J, Cui H, ym. Automated insulin delivery in pregnant women with type 1 diabetes: a systematic review and meta-analysis. Acta Diabetol 2025;62(8):1325-1335 «PMID: 39821308»PubMed
  142. Yang Q, Zeng B, Hao J, ym. Real-world glycaemic outcomes of automated insulin delivery in type 1 diabetes: A meta-analysis. Diabetes Obes Metab 2024;26(9):3753-3763 «PMID: 38888056»PubMed
  143. Zhou Y, Sardana D, Kuroko S, ym. Comparing the glycaemic outcomes between real-time continuous glucose monitoring (rt-CGM) and intermittently scanned continuous glucose monitoring (isCGM) among adults and children with type 1 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabet Med 2024;41(3):e15280 «PMID: 38197238»PubMed
Artikkelin tunnus: nix03604 (050.116)
© 2025 Suomalainen Lääkäriseura Duodecim

Käypä hoito -suositus

Anna palautetta
Linkkien värikoodit